

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

12 Jun 2026

### Effect of oral propranolol in retinopathy of prematurity

#### Protocol summary

##### Study aim

The Effect of Oral Propranolol Treatment on Preterm Retinopathy

##### Design

A clinical trial with a control and case group, single-blind, randomized

##### Settings and conduct

This study was performed at the NICU of Shahid Sadoughi hospital in Yazd. The case group received 0.5 mg/kg/dose oral of propranolol every 12 hours. The retinopathy process in neonates of both groups was monitored every week until the final status of ROP was determined by retinal fixation without knowledge of the neonates of each group.

##### Participants/Inclusion and exclusion criteria

The study included preterm infants who had been admitted to NICU. twenty-seven newborns were included based on the following criteria: infants born with > 26 weeks' gestation ; birth weight < 1500 g; and retinopathy Grade I and II. The exclusion criteria were that the gestational age of < 26 weeks, Intra-ventricular hemorrhage (IVH) Grade II and III, neonates with congenital anomalies, Heart disease except Patent Ductus Arteriosus (PAD) , congenital infectious (TORCH) and acute sepsis.

##### Intervention groups

infants were randomly assigned to two group. the control group, does not receive any drug. In the case group, the initial dose of oral propranolol was 0.25 mg/kg/dose for 2 days. Then received to 0.5 mg/kg body weight/dose every 12 h.

##### Main outcome variables

Improvement in retinopathy, need for laser therapy, the need for injection of Bevacizumab, Complications of propranolol in the intervention group, hemodynamic variables before and 24 hours after the start of treatment in the case group, duration of drug in the intervention group according to the response to treatment

#### General information

##### Reason for update

##### Acronym

ROP

##### IRCT registration information

IRCT registration number: **IRCT20100520003982N1**

Registration date: **2019-01-23, 1397/11/03**

Registration timing: **retrospective**

Last update: **2019-01-23, 1397/11/03**

Update count: **0**

##### Registration date

2019-01-23, 1397/11/03

##### Registrant information

##### Name

**Name of organization / entity**

##### Country

Iran (Islamic Republic of)

##### Phone

09131584474

##### Email address

dr.akrammirjalili@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2017-07-07, 1396/04/16

##### Expected recruitment end date

2018-07-07, 1397/04/16

##### Actual recruitment start date

2017-07-07, 1396/04/16

##### Actual recruitment end date

2018-11-04, 1397/08/13

##### Trial completion date

2018-12-21, 1397/09/30

##### Scientific title

Effect of oral propranolol in retinopathy of prematurity

## Public title

Effect of propranolol in retinopathy

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Preterm infants less than 1500 gr Preterm infants with gestational age greater than 26 weeks and less than 32 weeks Preterm infants with retinopathy grade I and II ROP Preterm infants admitted to NICU.

### Exclusion criteria:

Congenital malformation cardiovascular problems except Patent Ductus Arteriosus (PAD) active sepsis Congenital infections (TORCH) Intraventricular hemorrhage (IVH) Grade II and III

## Age

From **182 days** old to **224 days** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Care provider
- Outcome assessor
- Data analyser

## Sample size

Target sample size: **60**

Actual sample size reached: **27**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization was done using a random number table . To use the random numbers table, we considered the table numbers from the left to read the table numbers. Then, by placing a number and moving in the left direction, the odd numbers for control and the pair numbers were considered for intervention.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

The doctor examines newborns without knowing the grouping of them . Also, the Data analyzer did not know the groups and identified them as groups A and B.

## Placebo

Not used

## Assignment

Other

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Shahid Sadoughi University of

Medical Sciences, Yazd

#### Street address

Alam Square,Safayeh

#### City

Yazd

#### Province

Yazd

#### Postal code

8916978477

#### Approval date

2017-07-07, 1396/04/16

#### Ethics committee reference number

IR-MEDICIN.REG.1396.48

## Health conditions studied

### 1

#### Description of health condition studied

Retinopathy of prematurity

#### ICD-10 code

H35.1

#### ICD-10 code description

Retinopathy of prematurity

## Primary outcomes

### 1

#### Description

Retinopathy process

#### Timepoint

On the 28th day after birth (before entering the study), every week until the end of study

#### Method of measurement

Indirect ophthalmoscopy

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Oral propranolol (prilol 10 from OLIDARU): Start with dose of 0.25 mg / kg / dday for two days , then take 0.5mg / kg / day every 12 hours until the patient needs laser therapy or intra-ocular injection, or healing is complete without an aggressive treatment.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: does not receive any drugs. Ophthalmic examinations (indirect ophthalmoscopy) were performed on a weekly basis from day 28 of birth for all infants admitted to the neonatal intensive care unit.In the absence of improvement in the baby, aggressive

therapies including laser therapy and Bevacizumab injections were performed.

**Category**

Other

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Neonatal Neonatal Intensive Care Unit - Shahid Sadoughi Hospital, Yazd

**Full name of responsible person**

Dr. Mahmood Noori Shadkam

**Street address**

Shahid Sadoughi Hospital, Sina rd, Shahid Ghandi Buval

**City**

Yazd

**Province**

Yazd

**Postal code**

8915887857

**Phone**

+98 35 8224 0009

**Email**

medschool@ssu.ac.ir

**Web page address**

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Akrm Mirjalili

**Street address**

Paknezhad Bulvar

**City**

Yazd

**Province**

Yazd

**Postal code**

8916976745

**Phone**

+98 35 3726 4881

**Email**

dr.akrammirjalili@yahoo.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Yazd University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Persons

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Akram Mirjalili

**Position**

Specialist Non-Faculty

**Latest degree**

Specialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Paknezhad Bulvar

**City**

Yazd

**Province**

Yazd

**Postal code**

8916976745

**Phone**

+98 35 3726 4881

**Email**

dr.akrammirjalili@yahoo.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Doctor Mahmood Noori Shadkam

**Position**

Associated Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Shahid Sadoughi Hospital , Shahid Ghandi ST , Atlasi SQ , Safaieh

**City**

YAZD

**Province**

Yazd

**Postal code**

8915887857

**Phone**

+98 35 3811 3277

**Email**

Noorishadkam@ssu.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Akram Mirjalili

**Position**

Specialist Non-Faculty

**Latest degree**

Specialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Paknezhad Bulvar

**City**

Yazd

**Province**

Yazd

**Postal code**

8916976745

**Phone**

+98 35 3726 4881

**Email**

dr.akrammirjalili@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available